MATRIX LABS
PharmaMATRIX LABS is a pharmaceutical company focused on Immunology, Infectious Disease. Key products include LAMIVUDINE; ZIDOVUDINE.
MATRIX LABS's Key Drugs
MATRIX LABS's core commercial portfolio centers on AMLODIPINE AND OLMESARTAN MEDOXOMIL, EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE, LAMIVUDINE; ZIDOVUDINE, spanning Immunology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
MATRIX LABS's Recent FDA Approvals
New NDA/BLA approvals for MATRIX LABS over the last two years — novel drugs only, excluding generics and label supplements.
MATRIX LABS's Therapeutic Areas
MATRIX LABS's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MATRIX LABS's Top Competitors
MATRIX LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MATRIX LABS Pipeline Snapshot
Active clinical trials for MATRIX LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE AND OLMESARTAN MEDOXOMIL leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 16